Načítá se...
Assessment and Development of the Antifungal Agent Caspofungin for Aerosolized Pulmonary Delivery
Invasive Pulmonary Aspergillosis (IPA) and Pneumocystis jiroveci Pneumonia (PCP) are serious fungal pulmonary diseases for immunocompromised patients. The brand name drug CANCIDAS(®) (Caspofungin acetate for injection) is FDA approved to treat IPA, but is only 40% effective. Efficacious drug levels...
Uloženo v:
| Vydáno v: | Pharmaceutics |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8067632/ https://ncbi.nlm.nih.gov/pubmed/33916988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13040504 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|